Michael LaCascia - Foghorn Therapeutics Chief Officer
| FHTX Stock | USD 7.62 0.41 5.11% |
Insider
Michael LaCascia is Chief Officer of Foghorn Therapeutics
| Age | 59 |
| Address | 500 Technology Square, Cambridge, MA, United States, 02139 |
| Phone | 617 586 3100 |
| Web | https://foghorntx.com |
Foghorn Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2045) % which means that it has lost $0.2045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn Therapeutics' management efficiency ratios could be used to measure how well Foghorn Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn Therapeutics' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to rise to 0.13 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MPA MD | Unicycive Therapeutics | 51 | |
| Carrie Cox | Candel Therapeutics | 66 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Francesca MD | Candel Therapeutics | 46 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| FMEDSCI MD | Candel Therapeutics | 62 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Nathan Caffo | Candel Therapeutics | 55 | |
| Wilson Wong | Senti Biosciences | N/A | |
| Jason Amello | Candel Therapeutics | 56 | |
| Seshu Tyagarajan | Candel Therapeutics | 56 | |
| James Foster | Virax Biolabs Group | 39 | |
| Inf MD | Candel Therapeutics | 64 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Philip Lee | Senti Biosciences | 42 | |
| Ileen Winick | Candel Therapeutics | N/A | |
| James Collins | Senti Biosciences | 58 | |
| Susan Kahlert | Senti Biosciences | N/A | |
Management Performance
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 |
Foghorn Therapeutics Leadership Team
Elected by the shareholders, the Foghorn Therapeutics' board of directors comprises two types of representatives: Foghorn Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foghorn. The board's role is to monitor Foghorn Therapeutics' management team and ensure that shareholders' interests are well served. Foghorn Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foghorn Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saurabh Sewak, Vice Development | ||
| Karin Hellsvik, Corporate VP | ||
| Kristian MBA, Chief Officer | ||
| Adrian Gottschalk, CEO President | ||
| Stephen DiPalma, Treasurer CFO | ||
| Allan MD, Chief Officer | ||
| Alfonso MD, Chief Officer | ||
| Michael GarciaWebb, VP Research | ||
| Gerald Md, Founder Board | ||
| Fanny Cavalie, Chief Officer | ||
| Carlos Costa, Chief Officer | ||
| Michael JD, Chief Officer | ||
| Ben Strain, VP Communications | ||
| Michael LaCascia, Chief Officer | ||
| Anna Rivkin, Chief Officer | ||
| Steven Bellon, Chief Officer | ||
| MPH MD, Chief Officer |
Foghorn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foghorn Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (3.05) % | ||||
| Current Valuation | 218.09 M | ||||
| Shares Outstanding | 55.59 M | ||||
| Shares Owned By Insiders | 18.98 % | ||||
| Shares Owned By Institutions | 72.10 % | ||||
| Number Of Shares Shorted | 983.47 K | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 17.50 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.